Stereoselective analysis of hydroxybupropion and application to drug interaction studies

Chirality

Volumn 19, Issue 3, 2007, Pages 163-170

  Xu, Hongmei ^a   Loboz, Katarzyna K ^a   Gross, Annette S ^b   McLachlan, Andrew J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GLAXOSMITHKLINE   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Bupropion; Enantiomers; HPLC; Hydroxybupropion; Metabolite; Pharmacokinetics; Rifampicin

Indexed keywords

ACETONITRILE; AMFEBUTAMONE; AMMONIUM ACETATE; DRUG METABOLITE; HYDROXYBUPROPION; PHENACETIN; RIFAMPICIN; TRIETHYLAMINE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; ASSAY; BLOOD LEVEL; DRUG STRUCTURE; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MALE; MATHEMATICAL PARAMETERS; PLASMA; PRIORITY JOURNAL; RACEMIZATION; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STEREOCHEMISTRY;

ANTIBIOTICS, ANTITUBERCULAR; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; RIFAMPIN; STEREOISOMERISM;

EID: 33847195073     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20356     Document Type: Article

References (27)

1. Johnston JA, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 2002;62:S11-S24.
2. Haustein KO. Bupropion: Pharmacological and clinical profile in smoking cessation. Int J Clin Pharmacol Ther 2003;41:56-66.
3. Fang QK, Han Z, Grover P, Kessler D, Senanayake CH, Wald SA. Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an [α]-ketotriflate. Tetrahedron 2000;11:3659-3663.
4. Laizure SC, DeVane CL, Stewart JT, Dommisse CS, Lai AA. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther 1985;38:586-589.
5. Loboz KK, Gross AG, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. CYP2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampicin and ethnicity. Clin Pharmacol Ther (in press).
6. Welch RM, Lai AA, Schroeder DH. Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 1987;17:287-298.
7. Suckow RF, Zhang MF, Cooper TB. Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography. Biomed Chromatogr 1997;11:174-179.
8. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-1230.
9. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 2001;29:1123-1129.
10. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37:737-743.
11. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA Jr, Wilson JT, Manno JE. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001;41:770-778.
12. Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35:876-884.
13. Bondarev ML, Bondareva TS, Young R, Glennon RA. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 2003;474:85-93.
14. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004;66:675-682.
15. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999;288:88-92.
16. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295:321-327.
17. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31:282-288.
18. Madan A, Graham RA Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-431.
19. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299:849-857.
20. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and lexicological consequences in humans. Clin Pharmacokinet 2000;38:493-504.
21. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-341.
22. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56:1329-1339.
23. Goodwin B, Moore LB, Stoltz CM, McKee DD, Wiewer SA. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60:427-431.
24. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004;32:348-358.
25. Loboz KK, Gross AG, Ray J, McLachlan AJ. HPLC assay for bupropion and its major metabolites in human plasma. J Chromatogr B 2005;823:115-121.
26. Suckow RF, Smith TM, Perumal AS, Cooper TB. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dispos 1986;14:692-697.
27. Musso DL, Mehta NB, Soroko FE, Ferris RM, Hollingsworth EB, Kenney BT. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chirality 1993;5:495-500.